Company news

PAVmed Inc. news in 2025

PAVmed Inc.'s news releases, calls and decks from 2025, newest first.

View company

PAVmed Announces Reverse Stock Split

December 30, 2025

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

December 9, 2025

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

November 20, 2025

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

November 13, 2025

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 12, 2025

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

October 30, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

October 29, 2025

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

October 15, 2025

PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

October 7, 2025

Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

September 25, 2025

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

September 16, 2025

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

September 11, 2025

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

September 10, 2025

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

September 9, 2025

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

September 5, 2025

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

August 27, 2025

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

August 26, 2025

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

August 14, 2025

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025

Lucid Diagnostics to Participate in Upcoming Investor Conferences

August 5, 2025

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

July 31, 2025

PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

July 30, 2025

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

July 16, 2025

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

June 24, 2025

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

June 18, 2025

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

June 3, 2025

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

May 27, 2025

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

May 15, 2025

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14, 2025

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

May 1, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

April 30, 2025

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

March 11, 2025

PAVmed and Subsidiary Veris Health Complete Private Placement Financing

February 24, 2025

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

February 18, 2025

Calls in 2025

Decks in 2025